The expansion includes two new THC flower products in New Zealand and four new resin cartridges in Australia.
EDMONTON — Aurora Cannabis Inc., a Canadian-based medical cannabis company, is expanding its Aurora medical portfolio in Australia and New Zealand. The expansion aims to meet the needs of patients and healthcare professionals in the region and reflects Aurora’s focus on long-term global growth.
Per a Feb. 11 press release, the expansion in New Zealand includes two new THC flower products – Big Wave™, Night Ride ™, as well as, Half Moon™ reportedly coming soon in Q1 FY27. The brand will also intends to debut four new resin cartridges in Australia this month including, Chemango™ Kush, Cosmic Cream™, Lunar Express™, and Soul Train Haze™.
“With Australia being one of our largest international medical cannabis market, both Australia and New Zealand remain a top priority for Aurora, and we are deeply committed to our continued investment across the region,” says Stanley Sack, Interim Managing Director of MedReleaf Australia. “As patient needs evolve, so does our responsibility to deliver high‑quality, diversified product formats that support prescribers in delivering better care. Our focus on quality and reliable supply reflects our dedication to ensuring patients have meaningful access to the products they depend on.”
Each product is derived from Aurora’s proprietary genetics and manufactured at the company’s EU-GMP and TGA-GMP certified facilities in Canada.
New Zealand Launches:
- Big Wave™ – Flower, Hybrid, THC 26%, CBD <1%
- Night Ride™ – Flower, Indica, THC 29%, CBD <1%
- Half Moon™ – Flower, Hybrid, THC 9%, CBD 13%
Australia Launches:
- Chemango™ Kush – Resin Cartridge, Indica, THC 780mg/g, CBD <10mg/g
- Cosmic Cream™ – Resin Cartridge, Indica, THC 780 mg/g, CBD <10mg/g
- Lunar Express™ – Resin Cartridge, Indica, THC 780mg/g, CBD <10mg/g
- Soul Train Haze™ – Resin Cartridge, Sativa, THC 780mg/g, CBD <10mg/g
